StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research note released on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Trading Down 2.4 %
MediciNova stock opened at $1.21 on Monday. MediciNova has a 1-year low of $1.12 and a 1-year high of $2.49. The firm’s fifty day simple moving average is $1.31 and its 200-day simple moving average is $1.36. The company has a market capitalization of $59.35 million, a P/E ratio of -7.12 and a beta of 0.72.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in MediciNova stock. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of MediciNova, Inc. (NASDAQ:MNOV – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,000 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. 9.90% of the stock is owned by institutional investors.
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Recommended Stories
- Five stocks we like better than MediciNova
- 3 Tickers Leading a Meme Stock Revival
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- 3 Warren Buffett Stocks to Buy Now
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- 3 Best Fintech Stocks for a Portfolio Boost
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.